Logo image of CLBT

CELLEBRITE DI LTD (CLBT) Stock Fundamental Analysis

USA - NASDAQ:CLBT - IL0011794802 - Common Stock

16.62 USD
-0.44 (-2.58%)
Last: 11/3/2025, 8:00:01 PM
16.5 USD
-0.12 (-0.72%)
Pre-Market: 11/4/2025, 4:58:09 AM
Fundamental Rating

5

Taking everything into account, CLBT scores 5 out of 10 in our fundamental rating. CLBT was compared to 284 industry peers in the Software industry. While CLBT has a great health rating, its profitability is only average at the moment. CLBT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

CLBT had positive earnings in the past year.
In the past year CLBT had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: CLBT reported negative net income in multiple years.
CLBT had a positive operating cash flow in each of the past 5 years.
CLBT Yearly Net Income VS EBIT VS OCF VS FCFCLBT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

CLBT has a Return On Assets of -19.17%. This is in the lower half of the industry: CLBT underperforms 70.77% of its industry peers.
Looking at the Return On Equity, with a value of -36.96%, CLBT is doing worse than 64.08% of the companies in the same industry.
The Return On Invested Capital of CLBT (10.23%) is better than 85.92% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for CLBT is below the industry average of 11.83%.
The last Return On Invested Capital (10.23%) for CLBT is above the 3 year average (7.06%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -19.17%
ROE -36.96%
ROIC 10.23%
ROA(3y)-9.14%
ROA(5y)-1.85%
ROE(3y)-54.72%
ROE(5y)N/A
ROIC(3y)7.06%
ROIC(5y)7.59%
CLBT Yearly ROA, ROE, ROICCLBT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 100 -100 -200

1.3 Margins

Looking at the Operating Margin, with a value of 14.16%, CLBT is in the better half of the industry, outperforming 79.93% of the companies in the same industry.
CLBT's Operating Margin has improved in the last couple of years.
CLBT has a Gross Margin of 84.38%. This is amongst the best in the industry. CLBT outperforms 91.90% of its industry peers.
In the last couple of years the Gross Margin of CLBT has remained more or less at the same level.
Industry RankSector Rank
OM 14.16%
PM (TTM) N/A
GM 84.38%
OM growth 3Y10.9%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.66%
GM growth 5Y1.3%
CLBT Yearly Profit, Operating, Gross MarginsCLBT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), CLBT is creating some value.
CLBT has more shares outstanding than it did 1 year ago.
CLBT has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CLBT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CLBT Yearly Shares OutstandingCLBT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
CLBT Yearly Total Debt VS Total AssetsCLBT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

CLBT has an Altman-Z score of 7.47. This indicates that CLBT is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of CLBT (7.47) is better than 77.11% of its industry peers.
There is no outstanding debt for CLBT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 7.47
ROIC/WACC1.15
WACC8.93%
CLBT Yearly LT Debt VS Equity VS FCFCLBT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 1.96 indicates that CLBT should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.96, CLBT is in line with its industry, outperforming 59.86% of the companies in the same industry.
A Quick Ratio of 1.92 indicates that CLBT should not have too much problems paying its short term obligations.
CLBT's Quick ratio of 1.92 is in line compared to the rest of the industry. CLBT outperforms 59.86% of its industry peers.
Industry RankSector Rank
Current Ratio 1.96
Quick Ratio 1.92
CLBT Yearly Current Assets VS Current LiabilitesCLBT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 16.75% over the past year.
CLBT shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.48%.
The Revenue has been growing by 18.47% on average over the past years. This is quite good.
EPS 1Y (TTM)16.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)20.48%
Revenue growth 3Y17.68%
Revenue growth 5Y18.47%
Sales Q2Q%18.35%

3.2 Future

CLBT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.94% yearly.
The Revenue is expected to grow by 15.18% on average over the next years. This is quite good.
EPS Next Y18.9%
EPS Next 2Y12.72%
EPS Next 3Y12.96%
EPS Next 5Y12.94%
Revenue Next Year17.63%
Revenue Next 2Y17.21%
Revenue Next 3Y17.04%
Revenue Next 5Y15.18%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
CLBT Yearly Revenue VS EstimatesCLBT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M
CLBT Yearly EPS VS EstimatesCLBT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 0.2 0.4 0.6

3

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 36.13, the valuation of CLBT can be described as expensive.
CLBT's Price/Earnings ratio is a bit cheaper when compared to the industry. CLBT is cheaper than 61.27% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.51, CLBT is valued a bit more expensive.
Based on the Price/Forward Earnings ratio of 31.15, the valuation of CLBT can be described as expensive.
Based on the Price/Forward Earnings ratio, CLBT is valued a bit cheaper than 61.62% of the companies in the same industry.
CLBT is valuated rather expensively when we compare the Price/Forward Earnings ratio to 22.53, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 36.13
Fwd PE 31.15
CLBT Price Earnings VS Forward Price EarningsCLBT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

66.55% of the companies in the same industry are more expensive than CLBT, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, CLBT is valued a bit cheaper than 73.94% of the companies in the same industry.
Industry RankSector Rank
P/FCF 27.27
EV/EBITDA 45.53
CLBT Per share dataCLBT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
CLBT's earnings are expected to grow with 12.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.91
PEG (5Y)N/A
EPS Next 2Y12.72%
EPS Next 3Y12.96%

0

5. Dividend

5.1 Amount

CLBT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CELLEBRITE DI LTD

NASDAQ:CLBT (11/3/2025, 8:00:01 PM)

Premarket: 16.5 -0.12 (-0.72%)

16.62

-0.44 (-2.58%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-12 2025-11-12/bmo
Inst Owners44.23%
Inst Owner Change0.51%
Ins Owners2.65%
Ins Owner ChangeN/A
Market Cap4.06B
Revenue(TTM)436.73M
Net Income(TTM)-150948000
Analysts84.29
Price Target24.14 (45.25%)
Short Float %5.83%
Short Ratio4.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.37%
Min EPS beat(2)12.81%
Max EPS beat(2)15.93%
EPS beat(4)4
Avg EPS beat(4)21.79%
Min EPS beat(4)0.93%
Max EPS beat(4)57.51%
EPS beat(8)8
Avg EPS beat(8)51.82%
EPS beat(12)11
Avg EPS beat(12)53.22%
EPS beat(16)13
Avg EPS beat(16)50.32%
Revenue beat(2)0
Avg Revenue beat(2)-2.3%
Min Revenue beat(2)-3.58%
Max Revenue beat(2)-1.03%
Revenue beat(4)1
Avg Revenue beat(4)-0.52%
Min Revenue beat(4)-3.58%
Max Revenue beat(4)2.78%
Revenue beat(8)5
Avg Revenue beat(8)0.93%
Revenue beat(12)7
Avg Revenue beat(12)0.54%
Revenue beat(16)9
Avg Revenue beat(16)0.41%
PT rev (1m)2.9%
PT rev (3m)-5.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.51%
EPS NY rev (1m)0%
EPS NY rev (3m)6.69%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.88%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.09%
Valuation
Industry RankSector Rank
PE 36.13
Fwd PE 31.15
P/S 9.3
P/FCF 27.27
P/OCF 25.22
P/B 9.95
P/tB 11
EV/EBITDA 45.53
EPS(TTM)0.46
EY2.77%
EPS(NY)0.53
Fwd EY3.21%
FCF(TTM)0.61
FCFY3.67%
OCF(TTM)0.66
OCFY3.96%
SpS1.79
BVpS1.67
TBVpS1.51
PEG (NY)1.91
PEG (5Y)N/A
Graham Number4.16
Profitability
Industry RankSector Rank
ROA -19.17%
ROE -36.96%
ROCE 12.96%
ROIC 10.23%
ROICexc 926.92%
ROICexgc N/A
OM 14.16%
PM (TTM) N/A
GM 84.38%
FCFM 34.12%
ROA(3y)-9.14%
ROA(5y)-1.85%
ROE(3y)-54.72%
ROE(5y)N/A
ROIC(3y)7.06%
ROIC(5y)7.59%
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)8.94%
ROCE(5y)9.6%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y10.9%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.66%
GM growth 5Y1.3%
F-Score5
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 114.28%
Cap/Sales 2.77%
Interest Coverage 250
Cash Conversion 222.39%
Profit Quality N/A
Current Ratio 1.96
Quick Ratio 1.92
Altman-Z 7.47
F-Score5
WACC8.93%
ROIC/WACC1.15
Cap/Depr(3y)92.67%
Cap/Depr(5y)99.76%
Cap/Sales(3y)2.81%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y18.9%
EPS Next 2Y12.72%
EPS Next 3Y12.96%
EPS Next 5Y12.94%
Revenue 1Y (TTM)20.48%
Revenue growth 3Y17.68%
Revenue growth 5Y18.47%
Sales Q2Q%18.35%
Revenue Next Year17.63%
Revenue Next 2Y17.21%
Revenue Next 3Y17.04%
Revenue Next 5Y15.18%
EBIT growth 1Y23.19%
EBIT growth 3Y30.51%
EBIT growth 5YN/A
EBIT Next Year32.85%
EBIT Next 3Y23.1%
EBIT Next 5Y19.13%
FCF growth 1Y160.75%
FCF growth 3Y63.25%
FCF growth 5Y65.07%
OCF growth 1Y150.74%
OCF growth 3Y54.2%
OCF growth 5Y52.3%

CELLEBRITE DI LTD / CLBT FAQ

What is the fundamental rating for CLBT stock?

ChartMill assigns a fundamental rating of 5 / 10 to CLBT.


Can you provide the valuation status for CELLEBRITE DI LTD?

ChartMill assigns a valuation rating of 3 / 10 to CELLEBRITE DI LTD (CLBT). This can be considered as Overvalued.


What is the profitability of CLBT stock?

CELLEBRITE DI LTD (CLBT) has a profitability rating of 5 / 10.


What are the PE and PB ratios of CELLEBRITE DI LTD (CLBT) stock?

The Price/Earnings (PE) ratio for CELLEBRITE DI LTD (CLBT) is 36.13 and the Price/Book (PB) ratio is 9.95.


Can you provide the financial health for CLBT stock?

The financial health rating of CELLEBRITE DI LTD (CLBT) is 7 / 10.